Opportunity Information: Apply for RFA HL 14 017
Apply for RFA HL 14 017
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Onsite Tools and Technologies for Heart, Lung, and Blood Clinical Research Point of Care STTR (R41/R42)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.233 National Center on Sleep Disorders Research 93.350 National Center for Advancing Translational Sciences 93.837 Cardiovascular Diseases Research 93.838 Lung Diseases Research 93.839 Blood Diseases and Resources Research.
- This funding opportunity was created on Aug 15, 2013 and posted on Aug 15, 2013.
- Applicants must submit their applications by Oct 15, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses.
- Other Eligible Applicants include the following Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Onsite Tools and Technologies for Heart, Lung, and Blood Clinical Research Point of Care STTR (R41/R42)" (Funding Opportunity Number: RFA-HL-14-017) is a National Institutes of Health (NIH) Small Business Technology Transfer (STTR) solicitation focused on point of care (POC) solutions for clinical research and clinical settings. Its central aim is to push forward practical, onsite tools that can directly support decision-making in diagnosis and treatment for conditions involving the heart, lung, blood, and sleep disorders. The emphasis is on technologies that can be used where patients actually receive care or where clinical research is conducted, rather than tools that only work in specialized central labs or require lengthy turnaround times.
At a high level, the FOA is trying to accelerate both (1) the creation of new POC devices using advanced technologies and (2) the adaptation or implementation of existing technologies so they work reliably in real clinical environments. The underlying idea is that faster, more actionable measurements at or near the patient can improve how clinicians and researchers monitor disease, stratify risk, select therapies, and track response to treatment. While the announcement is broad, the common thread is onsite usability and clinical relevance: the technology should meaningfully guide diagnostic or therapeutic efforts in heart, lung, blood, and sleep-related conditions.
This opportunity uses the NIH STTR phased grant mechanism, specifically R41 and R42. In practice, that means projects are generally expected to follow a staged development path, where early work demonstrates feasibility and de-risks the core approach (commonly associated with Phase I, R41), and later work advances development toward a more complete, clinically ready prototype or implementation (commonly associated with Phase II, R42). The STTR structure also implies a formal collaboration between a small business and a research institution, reflecting the program goal of moving innovations out of the lab and into usable health technologies through a commercialization-oriented partnership.
The funding instrument is a grant, and the activity area is health. The FOA sits within several NIH-related CFDA areas tied to cardiovascular, lung, blood, sleep disorders, and translational science, including 93.837 (Cardiovascular Diseases Research), 93.838 (Lung Diseases Research), 93.839 (Blood Diseases and Resources Research), 93.233 (National Center on Sleep Disorders Research), and 93.350 (National Center for Advancing Translational Sciences). That mix signals that proposals can span a range of clinical targets across these disease domains, as long as the work remains anchored in point of care applicability and clinical utility.
Eligibility is limited to small businesses, consistent with the STTR program. Foreign institutions are not eligible to apply as applicant organizations, and non-U.S. components of U.S. organizations are also not eligible. However, the FOA notes that foreign components, as defined under NIH policy, may be allowed in some circumstances, which typically means a U.S. applicant may include certain foreign-related elements if they are well-justified and comply with NIH rules. There is no cost sharing or matching requirement stated, so applicants are not required to provide matching funds as a condition of award.
From an administrative standpoint, the opportunity was posted and created on August 15, 2013, with an original and current closing date of October 15, 2016, and it was archived on November 15, 2016. Even though it is archived, the announcement remains useful as a reference for the type of projects NIH sought under this topic area, the framing of point of care clinical research needs, and the way NIH structured commercialization-oriented technology development in these disease spaces at the time.
For additional details, NIH provided the full announcement link at http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-14-017.html. For access or technical issues related to the electronic announcement, the contact listed is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
Frequently Asked Questions (FAQs)
What is the title and funding opportunity number for this grant?
The opportunity is titled "Onsite Tools and Technologies for Heart, Lung, and Blood Clinical Research Point of Care STTR (R41/R42)" and the Funding Opportunity Number is RFA-HL-14-017.
Which agency is offering this opportunity?
This is a National Institutes of Health (NIH) solicitation under the NIH Small Business Technology Transfer (STTR) program.
What is the main purpose of this funding opportunity?
The central aim is to accelerate practical, onsite point-of-care (POC) tools and technologies that can support decision-making for diagnosis and treatment in heart, lung, blood, and sleep-disorder contexts. The focus is on solutions that work where patients receive care or where clinical research is conducted, rather than relying on specialized central laboratories or long turnaround times.
What does "point of care" mean in the context of this FOA?
In this FOA, "point of care" refers to tools and technologies that can be used onsite (at or near the patient or within the clinical research setting) to provide faster, actionable measurements or information that directly informs diagnostic or therapeutic decisions.
What kinds of projects does the FOA encourage?
It emphasizes two broad categories: (1) creating new point-of-care devices using advanced technologies, and (2) adapting or implementing existing technologies so they function reliably in real clinical environments. Across both categories, the common requirement is onsite usability and clinical relevance for heart, lung, blood, and sleep-related conditions.
What clinical areas or disease domains are in scope?
The scope includes conditions involving the heart, lung, blood, and sleep disorders. Proposals can span a range of clinical targets across these domains as long as the project remains anchored in point-of-care applicability and clinical utility.
How is this opportunity intended to improve clinical care or research?
The FOA is framed around the idea that faster, more actionable onsite measurements can improve how clinicians and researchers monitor disease, stratify risk, select therapies, and track response to treatment in real time or near-real time.
What grant mechanism does this opportunity use?
This FOA uses the NIH STTR phased grant mechanism: R41 and R42.
What is the difference between R41 and R42 under this STTR solicitation?
Projects are generally expected to follow a staged development path. Phase I (commonly associated with R41) focuses on demonstrating feasibility and de-risking the core approach. Phase II (commonly associated with R42) advances development toward a more complete, clinically ready prototype or implementation.
Does this STTR opportunity require collaboration between organizations?
Yes. The STTR structure implies a formal collaboration between a small business and a research institution, reflecting the program goal of moving innovations from the lab into usable health technologies through a commercialization-oriented partnership.
What is the funding instrument and activity area?
The funding instrument is a grant, and the activity area is health.
Which CFDA areas are associated with this FOA?
The FOA is associated with several NIH-related CFDA areas tied to cardiovascular, lung, blood, sleep disorders, and translational science: 93.837 (Cardiovascular Diseases Research), 93.838 (Lung Diseases Research), 93.839 (Blood Diseases and Resources Research), 93.233 (National Center on Sleep Disorders Research), and 93.350 (National Center for Advancing Translational Sciences).
Who is eligible to apply?
Eligibility is limited to small businesses, consistent with the NIH STTR program.
Are foreign institutions eligible to apply as the applicant organization?
No. Foreign institutions are not eligible to apply as applicant organizations.
Are non-U.S. components of U.S. organizations eligible?
No. Non-U.S. components of U.S. organizations are also not eligible.
Can a U.S. applicant include any foreign components?
The FOA notes that foreign components (as defined under NIH policy) may be allowed in some circumstances. This typically means a U.S. applicant may include certain foreign-related elements if they are well-justified and comply with NIH rules.
Is cost sharing or matching required?
No cost sharing or matching requirement is stated, so applicants are not required to provide matching funds as a condition of award.
When was this opportunity posted and when did it close?
The opportunity was posted/created on August 15, 2013. The original and current closing date was October 15, 2016.
Is this funding opportunity still open?
No. It was archived on November 15, 2016, indicating it is no longer active for new submissions under that announcement.
If it is archived, why might this FOA still be useful?
Even though it is archived, it can still be useful as a reference for the types of point-of-care projects NIH sought in heart, lung, blood, and sleep-related areas, and for how NIH structured commercialization-oriented technology development under the STTR mechanism at that time.
Where can the full announcement be found?
The full NIH announcement link provided is: http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-14-017.html
Who is the listed contact for access or technical issues with the electronic announcement?
The contact listed is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
Browse more opportunities from the same category: Health
Next opportunity: Service Area Competition Additional Area (Round Mountain, CA and Cheyenne, WY)
Previous opportunity: Onsite Tools and Technologies for Heart, Lung, and Blood Clinical Research Point of Care SBIR (R43/R44)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HL 14 017
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HL 14 017) also looked into and applied for these:
| Funding Opportunity |
|---|
| Service Area Competition Additional Area (Round Mountain, CA and Cheyenne, WY) Apply for HRSA 14 100 Funding Number: HRSA 14 100 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Smallpox Research Oversight Activities Apply for EP IDS 13 003 Funding Number: EP IDS 13 003 Agency: Assistant Secretary for Preparedness and Response Category: Health Funding Amount: $290,000 |
| Library of Integrated Network Based Cellular Signatures (LINCS) Perturbation Induced Data and Signature Generation Centers (U54) Apply for RFA RM 13 013 Funding Number: RFA RM 13 013 Agency: National Institutes of Health Category: Health Funding Amount: $1,700,000 |
| State Vital Statistics Improvement Program Apply for CDC RFA SH12 12010203SUPP13 Funding Number: CDC RFA SH12 12010203SUPP13 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $110,000 |
| Cooperative Agreement on Occupational Health with the World Health Organization (WHO) Implementing World Health Assembly Resolution 60.26 Global Plan of Action for Workers Health 2008 2017 Apply for RFA OH 14 002 Funding Number: RFA OH 14 002 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $250,000 |
| NHLBI Investigator Initiated Resource Related Research Projects (R24) Apply for PAR 13 335 Funding Number: PAR 13 335 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| National Indian Health Outreach and Education III Apply for HHS 2013 IHS NIHOE 0003 Funding Number: HHS 2013 IHS NIHOE 0003 Agency: Indian Health Service Category: Health Funding Amount: $1,043,923 |
| PPHF 2013 Immunization Operational Guidelines for Immunization Programs and Immunization Information Systems (IIS) in IIS AFIX Integration financed solely by 2013 Prevention and Public Health Funds Apply for CDC RFA IP12 120101PPHF13 Funding Number: CDC RFA IP12 120101PPHF13 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $400,000 |
| Global Health Security Action Groups Early Alerting and Reporting (EAR) Project Apply for EP IDS 13 004 Funding Number: EP IDS 13 004 Agency: Assistant Secretary for Preparedness and Response Category: Health Funding Amount: $65,000 |
| Inner City Asthma Consortium (UM1) Apply for RFA AI 13 036 Funding Number: RFA AI 13 036 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Paul B. Beeson Clinical Scientist Development Award in Aging (K08) Apply for RFA AG 14 013 Funding Number: RFA AG 14 013 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Paul B. Beeson Patient Oriented Research Career Development Award in Aging (K23) Apply for RFA AG 14 014 Funding Number: RFA AG 14 014 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Bridges to the Doctorate (R25) Apply for PAR 13 341 Funding Number: PAR 13 341 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| ACCP Task Force for Mass Critical Care During a Disaster Apply for CDC RFA TP13 1303 Funding Number: CDC RFA TP13 1303 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $75,000 |
| Revision Requests for Active Alzheimers Disease Core Centers (P30) Apply for PAR 13 342 Funding Number: PAR 13 342 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NeuroNEXT Clinical Trials (U01) Apply for PAR 13 343 Funding Number: PAR 13 343 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Strengthening Local Capacity for Scientific Research and Knowledge Management in Health Sectors in Asia Apply for 486 13 000003 Funding Number: 486 13 000003 Agency: Thailand USAID Bangkok Category: Health Funding Amount: $15,000,000 |
| TECHNICAL ASSISTANCE TO OBTAIN STATE AND TERRITORIAL HEALTH DEPARTMENT INPUT FOR NATIONAL HEALTH SECURITY RELATED ACTIVITIES Apply for EP HIT 13 002 Funding Number: EP HIT 13 002 Agency: Assistant Secretary for Preparedness and Response Category: Health Funding Amount: $500,000 |
| TECHNICAL ASSISTANCE TO OBTAIN LOCAL LEVEL GOVERNMENTAL AND COMMUNITY INPUT FOR NATIONAL HEALTH SECURITY RELATED ACTIVITIES Apply for EP HIT 13 003 Funding Number: EP HIT 13 003 Agency: Assistant Secretary for Preparedness and Response Category: Health Funding Amount: $500,000 |
| NIDCR Small Grant Program for New Investigators (R03) Apply for PAR 13 348 Funding Number: PAR 13 348 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HL 14 017", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.